Source - SMW
Cambridge Cognition Holdings has secured the first contract for the recently launched CANTAB Recruit product.

The drug development industry faces increasing challenges and mounting costs in locating, identifying and recruiting cognitively impaired subjects for clinical trials. This results in expensive recruitment costs and delayed clinical trial completion. Patient recruitment alone amounts to one third of total trial costs1 with 80% of pharmaceutical development programmes being delayed due to unfulfilled enrolment numbers.

At 8:54am: (LON:COG) Cambridge Cognition Holdings share price was +2.5p at 74.5p